Will NNRTIs be driving forward again?

Affiliations

¹ HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, 1211 Geneva, Switzerland. Electronic address: alexandra.calmy@hcuge.ch.
² Department of Medicine, Kantonspital Baselland, University of Basel, Bruderholz, Switzerland.

Comment

Alexandra Calmy et al. Lancet HIV. 2018 May.

. 2018 May;5(5):e200-e201.

doi: 10.1016/S2352-3018(18)30037-7. Epub 2018 Mar 25.

¹ HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, 1211 Geneva, Switzerland. Electronic address: alexandra.calmy@hcuge.ch.
² Department of Medicine, Kantonspital Baselland, University of Basel, Bruderholz, Switzerland.

No abstract available

Comment on

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group. Molina JM, et al. Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25. Lancet HIV. 2018. PMID: 29592840 Clinical Trial.